Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
With
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Have two consecutive estimated glomerular filtration rate (eGFR) measurements \< 60 mL/min/1.73 m2 at least 92 days apart between April 17, 2014 and October 31, 2022.
2. Aged 18 years or older at the study cohort entry date.
3. Have at least one haemoglobin (Hb) measurement at the study cohort entry date or within 183 days before the study cohort entry date.
You may not be if
1. Have less than 183 days of record history before the study cohort entry date.
2. Have any prescription record for an SGLT2 inhibitor at the study cohort entry date or within 183 days before the study cohort entry date
3. Have evidence of anemia at the study cohort entry date or within 183 days before the study cohort entry date.
* Hemoglobin (Hb) \< 13.0 g/dL for men or \< 12.0 g/dL for women
* Hematocrit (Ht) \< 39% for men or \< 36% for women
* Have a history of prescribed anemia-related medications and treatments at the study cohort entry date or within 183 days before the study cohort entry date.
4. Have evidence of anemia-causing conditions other than chronic kidney disease (CKD) at the study cohort entry date or within 183 days before the study cohort entry date.
5. Confirm at least one instance of hemodialysis, peritoneal dialysis, or kidney transplantation at the study cohort entry date or within 183 days before the study cohort entry date.
Clareo Health | SGLT2 Inhibitors and Renal Anemia in Japan: RWD
